c-RET
The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
- Cat.No. 产品名称 Information
-
GC10111
Regorafenib
A multi-kinase inhibitor
-
GC15307
SU5416
A tyrosine kinase inhibitor
-
GC14534
Regorafenib monohydrate
A multi-kinase inhibitor
-
GC14606
Regorafenib hydrochloride
A multi-kinase inhibitor
-
GC16391
Amuvatinib (MP-470, HPK 56)
A multi-targeted RTK inhibitor
-
GC15217
Danusertib (PHA-739358)
A pan-Aurora kinase and Abl inhibitor
-
GC10035
TG101209
An inhibitor of JAK2, FLT3, RET, and JAK3